

Figure 2. NDM-producing CRE isolates, by genera, among isolates from specimens collected January 1, 2017 through June 30, 2019, United States (N=631)




Fig. 2.

predominated. Aggressive public health response and further understanding of current US NDM-CRE epidemiology are needed to prevent further spread.

Disclosures: None

Funding: None

Doi:[10.1017/ice.2020.502](https://doi.org/10.1017/ice.2020.502)

Presentation Type:

Oral Presentation

Chlorhexidine MICs Remain Stable Among Antibiotic-Resistant Bacterial Isolates Collected from 2005 to 2019 at Three US Sites

Joseph Lutgring, Centers for Disease Control and Prevention; Julian Grass, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention; David Lonsway, Centers for Disease Control and Prevention; Brian Yoo, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention; Erin Epton, California Department of Public Health, Healthcare-Associated Infections Program; Megan Crumpler, Orange County Health Care Agency; Karen Galliher, Orange County Health Care Agency; Kathleen O'Donnell, California Department of Public Health; Matthew Zahn, Orange County Health Care Agency; Eric Evans, Emory University, Rollins School of Public Health; Jesse Jacob, Emory University; Alexander Page, Georgia Emerging Infections Program; Sarah Satola, Emory University School of Medicine; Gillian Smith, Georgia Emerging Infections Program; Marion Kainer, Western Health; Mary Hayden, Rush University Medical Center; Sujan Reddy, Centers for Disease Control and Prevention; Christopher Elkins, Centers for Disease Control and Prevention; J. Kamile Rasheed; Maria Karlsson; Shelley Magill, Centers for Disease Control and Prevention; Alice Guh, Centers for Disease Control and Prevention

Background: Chlorhexidine bathing reduces bacterial skin colonization and prevents infections in specific patient populations. As chlorhexidine use becomes more widespread, concerns about bacterial tolerance to chlorhexidine have increased; however, testing for chlorhexidine minimum inhibitory concentrations (MICs) is challenging. We adapted a broth microdilution (BMD) method to determine whether chlorhexidine MICs changed over time among 4 important healthcare-associated pathogens. **Methods:** Antibiotic-resistant bacterial isolates (*Staphylococcus aureus* from 2005 to 2019 and *Escherichia coli*, *Klebsiella pneumoniae*, and *Enterobacter cloacae* complex from 2011 to 2019) were collected through Emerging Infections Program surveillance in 2 sites (Georgia and Tennessee) or through public health reporting in 1 site (Orange County, California). A convenience sample of isolates were collected from facilities with varying amounts of chlorhexidine use. We performed BMD testing using laboratory-developed panels with chlorhexidine digluconate concentrations ranging from 0.125 to 64 µg/mL. After successfully establishing reproducibility with quality control organisms, 3 laboratories performed MIC testing. For each organism, epidemiological cutoff values (ECVs) were established using ECOFFinder. **Results:** Among 538 isolates tested (129 *S. aureus*, 158 *E. coli*, 142 *K. pneumoniae*, and 109 *E. cloacae* complex), *S. aureus*, *E. coli*, *K. pneumoniae*, and *E. cloacae* complex ECVs were 8, 4, 64, and 64 µg/mL, respectively (Table 1). Moreover, 14 isolates had an MIC above the ECV (12 *E. coli* and 2 *E. cloacae* complex). The MIC₅₀ of each species is reported over time (Table 2). **Conclusions:** Using an adapted BMD method, we found that chlorhexidine MICs did not increase over time among a limited sample of *S. aureus*, *E. coli*, *K. pneumoniae*, and *E. cloacae* complex isolates. Although these results are reassuring, continued surveillance for elevated chlorhexidine MICs in isolates from patients with well-characterized chlorhexidine exposure is needed as chlorhexidine use increases.

Funding: None

Disclosures: None

Doi:[10.1017/ice.2020.503](https://doi.org/10.1017/ice.2020.503)

Table 1. Chlorhexidine MIC Results

Organism	MIC Range (µg/mL)	MIC ₅₀ (µg/mL)	MIC ₉₀ (µg/mL)	ECV (µg/mL)
<i>S. aureus</i>	1–8	2	4	8
<i>E. coli</i>	1–64	2	4	4
<i>K. pneumoniae</i>	4–64	16	32	64
<i>E. cloacae</i> complex	1–>64	16	64	64

Table 2. Chlorhexidine MIC₅₀ Results Over Time

Year	<i>S. aureus</i>		<i>E. coli</i>		<i>K. pneumoniae</i>		<i>E. cloacae</i> complex	
	n	MIC ₅₀ (µg/mL)	n	MIC ₅₀ (µg/mL)	n	MIC ₅₀ (µg/mL)	n	MIC ₅₀ (µg/mL)
2005–2007	27	4	0	N/A	0	N/A	0	N/A
2008–2010	18	4	0	N/A	0	N/A	0	N/A
2011–2013	25	4	8	2	25	16	2	N/A
2014–2016	43	2	27	2	20	16	23	16
2017–2019	16	2	123	2	97	16	84	16